Is there really apoptosis after acetaminophen overdose? An alarm to the misguided use of some apoptosis parameters resulting in wrong conclusions.Read more
An opinion piece based on the reasoning that early intervention with intravenous statin should block progression of hyper-inflammation in severe cases of COVID-19 infection thereby allowing recovery of patients otherwise destined to die.Read more
Read this newly publishedfrom Dr. Gurchetan Randhawa at Maimonides Medical Center of New York City.
Dr. Nicholas Murray is assistant professor and director of the Neuromechanics Laboratory, and the athletic research coordinator at the School of Community Health Sciences of University Of Nevada, Reno, United States. Dr. Murray's primary research approach is the investigation of oculomotor and postural control in individuals with acute or chronic neurological deficits with a focus on sports-related concussions and repeated head impacts.
Dr. Murray has recently edited a JCTR special issue on sport-related concussion: from the laboratory to the clinic. Please read the collection.
Dr. Felipe Couñago, Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society) Coordinator; Radiation Oncology Department, Hospital Universitario Quirónsalud Madrid; Hospital La Luz, Madrid; Universidad Europea de Madrid, Spain.
Dr. Juan Carlos Trujillo-Reyes, Thoracic Oncology Committee of the Spanish Society of Pneumology and Thoracic Surgery (SEPAR); Thoracic Surgery Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Dr. Antonio Calles, Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
Recent advances in radiological imaging and genomic analysis are profoundly changing the way to manage lung cancer patients. Screening programs which couple lung cancer risk prediction models and low-dose computed tomography (LDCT) recently showed their effectiveness in the early diagnosis of lung tumors. In addition, the emerging field of radiomics is revolutionizing the approach to handle medical images, i.e., from a "simple" visual inspection to a high-throughput analysis of hundreds of quantitative features of images which can predict prognosis and therapy response. Yet, with the advent of next-generation sequencing (NGS) and the establishment of large genomic consortia, the whole mutational and transcriptomic profile of lung cancer has been unveiled and made publicly available via web services interfaces. This has tremendously accelerated the discovery of actionable mutations, as well as the identification of cancer biomarkers, which are pivotal for development of personalized targeted therapies. The essence of precision medicine is to achieve the goal of "individualized treatment" through genotyping of patients and targeted therapy. Recent advances in the field of novel anticancer agents prolong patients' survival and show a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the two major areas undergoing rapid development. Advances in image navigation, radiation planning, and dose application have enabled successful introduction of SBRT as a treatment regimen for many primary tumors and oligometastatic disease. If surgery is not possible or the patient refuses surgery, it is always reasonable to consider SBRT. Despite the tremendous progress made in understanding lung tumour biology, advances in early diagnosis, multimodal therapy and deciphering molecular mechanisms of drug resistance, overall curative outcomes remain low, especially in metastatic disease. Nanotechnology, in particular nanoparticles (NPs), Big Data and Artificial Intelligence to progressively impact the way by which tumours are diagnosed and treated.
We welcome submissions of original research as well as review articles that address the new advances in the diagnosis and treatment of lung cancer. Potential topics include but are not limited to the following:
-Advanced molecular imaging
-Next-generation sequencing (NGS)
-Advances in surgery
-Advances in radiotherapy
-Big data and AI
Submission starting date: January 30, 2020
Submission deadline: September 30, 2020
Expected publication date: December 30, 2020
Please submit your paper along with a cover letter including the special issue title. Your paper will undergo a fair peer review, be published free of charge and immediately after acceptance, available to an international audience.
The editorial board is proud to announce that the National Library of Medicine has officially confirmed that the Journal of Clinical and Translational Research has been indexed in PubMed and PubMed Central. All papers previously accepted in JCTR have appeared online and can be retrieved. The editorial board is grateful to all who have contributed to this milestone, which includes our authors, our reviewers, and our editorial board members.
JCTR has prepared output style files for both EndNote and Mendeley users. Please contact ourto get a copy and make reference formatting easier.